Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Atherosclerosis
|
281 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2014 | 2015 | |||||
Bladder Neoplasm
|
281 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2011 | 2013 | |||||
Carcinoma of bladder
|
309 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2011 | 2013 | |||||
Finding of Mean Corpuscular Hemoglobin
|
1206 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.700 | 1.000 | 2 | 2016 | 2017 | |||||
Glioblastoma
|
281 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2011 | 2015 | |||||
Glioblastoma Multiforme
|
186 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2011 | 2015 | |||||
Lung Diseases, Interstitial
|
144 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.810 | 1.000 | 2 | 2013 | 2014 | |||||
Malignant neoplasm of colon and/or rectum
|
502 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 0.500 | 2 | 2012 | 2015 | |||||
Malignant neoplasm of prostate
|
1082 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2015 | 2015 | |||||
Malignant neoplasm of thyroid
|
103 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2016 | 2019 | |||||
Malignant neoplasm of urinary bladder
|
316 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2011 | 2013 | |||||
Platelet Count measurement
|
457 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.700 | 1.000 | 2 | 2016 | 2018 | |||||
Prostate carcinoma
|
1168 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2015 | 2015 | |||||
Squamous cell carcinoma
|
257 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2009 | 2010 | |||||
Thyroid Neoplasm
|
135 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2016 | 2019 | |||||
Adult Glioblastoma
|
98 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Adult Meningioma
|
30 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
80 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Atrial Fibrillation
|
584 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Brain Neoplasms
|
204 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.010 | 1 | 2013 | 2013 | ||||||
Carcinoma
|
103 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Carcinoma, Small Cell
|
7 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Childhood Acute Lymphoblastic Leukemia
|
261 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Childhood Glioblastoma
|
98 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Chromosome 10, monosomy 10q
|
4 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.010 | 1.000 | 1 | 2013 | 2013 |